Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥18 years old) male or female who will undergo surgery for fractured hip with general anesthesia within 72 hours of admission to hospital.~2. If female, subject is non-lactating and is either:~   1. Not of childbearing potential, defined as post-menopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.~  2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of birth control: oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.~3. Subject is American Society of Anesthesiologists Physical Status I, II, III, or IV.~4. Subject (or subject's legally authorized representative) has voluntarily signed and dated the informed consent document approved by the Institutional Review Board (IRB).~Exclusion Criteria:~1. Cognitive function level by Mini Mental State Exam (MMSE) of ≤20.~2. Subject has a positive CAM-ICU result for delirium at Screening or Baseline.~3. Subject requires chronic antipsychotic therapy.~4. Subject is anticipated to require additional surgical procedures during the 72 hour Screening Period and the 3 days Follow-up Period.~5. Subject is anticipated to require repair of pelvic fractures (eg,acetabulum).~6. Subject has participated in a trial with any experimental drug or experimental implantable device within 30 days prior to the study drug administration, or has ever been enrolled in this study.~7. Subject known to be in liver failure.~8. Subject has an anticipated potential for increased intracranial pressure or an uncontrolled seizure disorder or known psychiatric illness that could confound a normal response during study assessment.~9. Subject has received treatment with a α2-agonist or antagonist (within 14 days of study entry).~10. Subject for whom opiates, benzodiazepines, DEX or other α2-agonists are contraindicated.~11. Subject has, per the investigator's judgment, a known or suspected physical or psychological dependence on an abused drug, other than alcohol.~12. Subject has acute unstable angina, acute myocardial infarction, HR \<50 bpm, SBP \<90 mmHg, or third degree heart block unless the subject has a pacemaker.~13. Subject has any condition or factor which, in the Investigator's opinion, might increase the risk to the subject.~14. Subject is not expected to live more than 60 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): None
- Placebo (PBO) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy